` U.S. California
CASES DEATHS CASES DEATHS
December 2020 19,111,443 341,149 2,120,610 24,241
January 26,185,362 441,319 3,310,949 40,702
February 28,602,101 513,137 3,563,578 51,953
March 30,459,874 552,072 3,668,277 59,240
April 32,225,012 574,280 3,742 115 62,078
UPDATED WEEKLY - Last updated on 1 May, 2021 7:00 am PST, John Hopkins Corona Virus Dashboard and Worldometer
John Hopkins Worldometer
Recovered - 86,527,565 Recovered - 129,439,543
POPULATION - is 332,631,370 as of 1 May, 07:00 am PST, based on Census U.S. and World Population Clock.
Cases in the U.S.
Recovered - Recovered - 25,710,142
Cases in California
Recovered - Recovered - 1,992,268
2021 unemployment numbers are hovering around 8.5%.
05/01/2021 Cases (WHO) Deaths (WHO) Recovered (WHO)
**reporting information is limited, reduced testing and increased cases
United States progress Updated as of 18 April 2021, 12:15 pm
State Progress Updated as of 18 April 2021, 12:15 pm
. 1st dose 2nd dose Population %
President Biden directs all states to make all adults eligible for COVID-19 vaccine by May 1. President Biden set a goal of July 4 to "get closer to normal" in reopening the country. To reach that goal, the president is directing all states to make all American adults eligible for the COVID-19 vaccine by May 1. "It will make this Independence Day truly special, not only marking independence as a nation but independence from this virus. To attain this goal, I need every American to do their part," President Biden said.
As people are getting fully vaccinated, the Centers for Disease Control will update its guidance on activities like travel and attending church worship services. President Biden announced measures Tuesday, March 9th, aimed at ramping up coronavirus vaccine allocation and distribution, including the purchase of 200 million more vaccine doses and increased distribution to states by millions of doses.
With the additional doses, there would be enough vaccine to fully vaccinate 300 million Americans -- nearly the entire US population -- by the end of summer or early fall.
Pfizer-BioNTech says Covid vaccine is 100% effective in kids ages 12 to 15
Vaccinating children is crucial to ending the pandemic, public health officials and infectious disease experts say. The vaccine elicited a “robust” antibody response in children, exceeding those in an earlier trial of 16 - 25-year-olds. Children make up around 20% of the U.S. population. The nation is unlikely to achieve herd immunity until children can get vaccinated. 70% to 85% of the U.S. population needs to be vaccinated to achieve herd immunity.
Pfizer’s study of adolescents ages 12 to 15 is encouraging results that could clear the shots for use in middle school students before school starts this fall. The trial enrolled 2,260 participants in the United States. There were 18 confirmed Covid-19 infections observed in the placebo group and no confirmed infections in the group that received the vaccine, the company said. That resulted in a vaccine efficacy of 100%, adding that the shot was also well-tolerated, with side effects generally consistent with those seen in adults.
Moderna Gives 1st Vaccine Shots To Young Kids As Part Of COVID-19 Study. Moderna plans to enroll roughly 6,750 children in the U.S. and Canada for the study. Children received their first doses of Moderna's COVID-19 vaccine, as the company studies the safety and effectiveness of the vaccine for kid’s ages 6 months to less than 12 years old.
In the study, two injections 28 days apart of the Moderna vaccine or a saline placebo, was given to children. Children receiving the vaccine will receive one of three possible doses, from 25 micrograms to 100 micrograms — the same dose that received an emergency authorization for use in adults from the Food and Drug Administration.
COVID-19 vaccine could be cleared for use in the United States as soon as May. Preliminary data from its UK trial showed the vaccine to be 96% effective against the original version of the coronavirus and around 86% effective against the now widely circulating variant first discovered in Britain.
Novavax, NVX-CoV2373, can manufacture its shots at scale and able to have tens of millions of doses stockpiled and ready to ship in the United States when it receives authorization. Novavax promised to deliver 110 million doses to the U.S. government by the end of the third quarter or as early as July. NVX-CoV2373 is administered in liquid form and can be stored, handled and distributed at above-freezing temperatures, 35° to 46°F. Doses of Novavax can be stored for up to three months at fridge temperature. A single vaccine dose contains 5 micrograms (mcg) of protein and 50 mcg of adjuvant.
In a smaller trial conducted in South Africa, volunteers were primarily exposed to another newer, more contagious variant widely circulating there and spreading around the world. The Novavax vaccine was 55% effective, based on people without HIV, but still fully prevented severe illness.
Novavax Chief Medical Officer, Filip Dubovsky, indicated the performance in South Africa suggests there may be a case for using it in areas where the South African variant is dominant. Novavax is also developing new formulations of its vaccine to protect against emerging variants and plans to initiate clinical testing in the second quarter of this year.
How does the vaccine work? The Oxford-AstraZeneca vaccine is a shot designed to prevent the coronavirus in people aged 18 and older. It is made up of an adenovirus that has been modified to contain the gene for making a protein from SARS-CoV-2, the virus that causes Covid-19.
The most common side effects of the shot, which does not contain the virus and cannot cause Covid, are typically mild or moderate and improve within a few days of vaccination. Late-stage clinical trials found the AstraZeneca-Oxford shot to have an average efficacy of 70% in protecting against the virus.
A more recent study by Oxford researchers found the vaccine was 76% effective at preventing symptomatic infection for three months after a single dose, and that the efficacy rate actually rose with a longer interval between the first and second doses.
More countries suspend AstraZeneca vaccinations over blood clot fears: What we know so far.
Approximately, 5 million people in Europe had received the Oxford-AstraZeneca vaccine. Of this, 30 cases of thromboembolic events or blood clots forming in the blood vessels blocking blood flow have been reported.
Why are countries pausing vaccination campaigns? Thailand’s health ministry announced it would temporarily postpone use of the Oxford-AstraZeneca vaccine, describing the vaccine as a “good vaccine” but wishes to suspend use for safety investigations. Thailand’s decision to suspend its planned rollout of the Oxford-AstraZeneca vaccine came after the decision by the Danish Health Authority.
Kiattiphum Wongjit, Secretary for the Public Health Ministry, said the country was able to pause vaccinations by bringing a second wave of Covid cases under control through quarantines and border controls. Of approximately 70 million people, there are 26,600 recorded cases and 85 deaths, according to data by Johns Hopkins University. There is good evidence that the vaccine is both safe and effective.
The U.K., France, Australia, Canada and Mexico are some of the nations that sought to reassure citizens about the benefits of getting the vaccine and will continue inoculation campaigns. “An analysis of our safety data of more than 10 million records shows no evidence of an increased risk of pulmonary embolism or deep vein thrombosis in any defined age group, gender, batch or any particular country with COVID-19 Vaccine AstraZeneca,” said a spokesperson for AstraZeneca.
Earlier, top German public health officials said the vaccine was safe, adding that the country would continue to deploy it. With Germany still facing a scarcity of vaccines and a third wave of Covid-19, the government is anxious to ensure that vaccine hesitancy does not undermine the rollout to bring the pandemic under control.
AstraZeneca's COVID-19 shot will come too late for the US. There are two main reasons the vaccine experts said the shot from AstraZeneca and Oxford University won't be used much in the U.S. if at all.
Dr. Ashish Jha, a top US public-health expert, argued the U.S. should donate its supply of the vaccine to other countries, rather than reserve it for use domestically. "The time to use AZ in the U.S. would have been in January by May we won't need it." Dr. Fauci, the nation's top infectious-disease expert, indicated giving doses to other countries is on the table when the U.S. has an excess supply.
What do the experts say? Stephen Evans, Professor of Pharmaco-epidemiology at the London School of Hygiene & Tropical Medicine, said: “The problem with spontaneous reports of suspected adverse reactions to a vaccine is the enormous difficulty of distinguishing a causal effect from a coincidence. This is true when we know that Covid-19 disease is strongly associated with blood clotting and there have been hundreds of deaths caused by blood clotting as a result of Covid-19 disease. The first thing to do is to be absolutely certain that the clots did not have some other cause, including Covid-19,” Evans added.
The EMA’s safety committee is reviewing the issue, but said there is currently no evidence the vaccination caused blood clots, noting they are not listed as side effects of this vaccine. “Reports of blood clots received so far are not greater than the number that would have occurred naturally in the vaccinated population,” said Dr. Phil Bryan, vaccines safety lead at Britain’s Medicines and Healthcare Products Regulatory.
The World Health Organization has urged countries to continue administering doses of the Oxford/AstraZeneca coronavirus vaccine, saying there are no indications it is linked to the blood clots that have been reported in recent days.
Around 5 million Europeans have already received the AstraZeneca vaccine, whereas the figure is 11 million for Britain.
PREPARATION FOR THE VACCINE
It is not recommended to take antihistamines before getting a COVID-19 vaccine to try to prevent allergic reactions.
If you get a COVID-19 vaccine within 14 days of another vaccine, you do not need to be revaccinated with either vaccine. You should still complete both vaccine series on schedule.
When there is more data on the safety and effectiveness of COVID-19 vaccines given at the same time as other vaccines, the CDC may update this recommendation.
You should get your second shot as close to the recommended 3-week or 4-week interval as possible. However, your second dose may be given up to 6 weeks or 42 days after the first dose, if necessary. You should not get the second dose earlier than the recommended interval.
If you need help scheduling your vaccination appointment for your second shot, contact the location that set up your first appointment for assistance. This may be your state or local health department, employer, or vaccination provider.
What to expect after getting a COVID-19 vaccine
WHAT CAN WE DO? Until you are completely vaccinated, you can take basic precautions to reduce your family's risk of getting this and other illnesses by:
Stay safe. Mask. Social distance. Frequent hand washing. Avoid crowds.
ALWAYS CONSULT YOUR PERSONAL HEALTH CARE PROFESSIONAL
1756 N. Riverside Ave
Rialto, CA 92376
Phone: 909 879-1059
Fax : 909 879-1043
Monday 10 am - 4:00 pm Tuesday 10 am - 4:00 pm
Wednesday 10 am - 4:00 pm
Thursday 10 am - 4:00 pm
Friday 10 am - 4:00 pm
HOLIDAY HOURS MAY VARY
10:30 am - 3 pm
Phone orders are encouraged. Large orders prior to 10:30 am
Deliveries not available during covid restrictions.
Stop in to check out all the items currently discounted for your personal resolutions.